vadimezan has been researched along with Melanoma in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Banciu, M; Licarete, E; Luput, L; Mot, AC; Patras, L; Porfire, A; Rakosy-Tican, E; Rauca, VF; Sesarman, A; Toma, VA | 1 |
Cichoń, T; Jarosz-Biej, M; Kułach, N; Pilny, E; Poczkaj, A; Smolarczyk, R; Szala, S | 1 |
Chen, CJ; Ching, LM; Dunbar, PR; Henare, K; Print, C; Thomsen, L; Tijono, S; Wang, L; Wang, LC; Winkler, S | 1 |
Baguley, BC; Kelland, LR; Marshall, ES; Zhao, L | 1 |
Baguley, BC; Cao, Z; Ching, LM; Joseph, WR; Marshall, ES; Mountjoy, KG | 1 |
Laux, WT; Palmer, BN; Rutland, MD; Siim, BG; Wilson, WR | 1 |
6 other study(ies) available for vadimezan and Melanoma
Article | Year |
---|---|
Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Liposomes; Macrophages; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxidative Stress; Simvastatin; Skin Neoplasms; Tumor Microenvironment; Xanthones | 2021 |
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Digoxin; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Macrophages; Melanoma; Melanoma, Experimental; Mice; Neovascularization, Pathologic; Xanthones; Xenograft Model Antitumor Assays | 2018 |
Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Gene Regulatory Networks; Homeodomain Proteins; Humans; Leukocytes; Macrophages; Melanoma; Mice; Mice, Knockout; Mice, Nude; Oligonucleotide Array Sequence Analysis; Stromal Cells; Transcription, Genetic; Tumor Burden; Up-Regulation; Xanthones; Xenograft Model Antitumor Assays | 2012 |
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Line, Tumor; Cell Proliferation; Cell Shape; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Laminin; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proteoglycans; Pyridines; RNA, Messenger; Xanthones; Xenograft Model Antitumor Assays | 2007 |
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Lipopolysaccharides; Liver; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; RNA, Messenger; Spleen; Stimulation, Chemical; Transplantation, Heterologous; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1999 |
Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Fibrosarcoma; Humans; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Radiopharmaceuticals; Stilbenes; Xanthenes; Xanthones | 2000 |